| Study Period | 2022 - 2030 |
| Market Size (2025) | USD 1.22 Billion |
| Market Size (2030) | USD 1.93 Billion |
| CAGR (2025 - 2030) | 9.58 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Embryonic Stem Cells Market Analysis
The Human Embryonic Stem Cells Market size is estimated at USD 1.22 billion in 2025, and is expected to reach USD 1.93 billion by 2030, at a CAGR of 9.58% during the forecast period (2025-2030).
The expansion of the human embryonic stem cells market is driven by the high incidence of heart ailments and malignancies, the surging need for regenerative medicines, and the enhanced backing from both governmental and private organizations.
Government funding for the development of regenerative medicine has been increasing in most developed countries, owing to its applications in organ transplantation, tissue engineering, and various other applications. For instance, in September 2024, the Australian Government allocated USD 23.4 million (AUD 34.5 million) for research funding to test innovative treatments and therapies that seek to leverage the potential of stem cells to enhance patient outcomes for patients with osteoarthritis and other conditions. Additionally, in April 2023, the Board of the California Institute for Regenerative Medicine (CIRM) authorized nearly USD 89 million in stem cell and gene therapy research. Thus, such rising investments by the government to enhance stem cell research and develop innovative treatments are anticipated to drive market growth.
Additionally, other factors, such as the high prevalence of cardiac and malignant diseases and the rising demand for regenerative medicines, are expected to drive the market. For instance, according to the report published by the World Heart Federation in April 2023, approximately 620 million individuals globally were affected by heart and circulatory diseases in 2023. Additionally, as per the above-mentioned source, about 60 million people worldwide are diagnosed with a heart or circulatory condition annually. Such incidences of cardiac diseases are expected to drive the demand for effective therapeutics, such as embryonic stem cell therapies, thereby contributing to the market's growth.
The area of human embryonic stem cell-based therapies garners significant investments, and various clinical trials that require considerable support for expenditure are currently underway. Companies are fundraising to develop stem cell-based therapies to tackle many diseases. For instance, in September 2024, Evotec SE formed a technology development partnership with Novo Nordisk focused on cell therapy. As part of this collaboration, Novo Nordisk will provide funding for technology development efforts at Evotec to enhance stem cell-based therapies' clinical and commercial production. Such partnerships are expected to be pivotal in accelerating the development and commercialization of stem cell-based therapies, thereby contributing to the growth of the human embryonic stem cell market.
Additionally, in April 2024, Century Therapeutics expanded its research into autoimmune diseases through two agreements, providing the company with USD 60 million in additional funding and technology from a private startup, Clade Therapeutics. In addition, the acquisition of Clade Therapeutics for around USD 35 million will grant Century access to three preclinical programs and advanced technology for enhancing stem cell-derived therapies. Thus, market players' rising funding and investments to support stem-cell-based therapy development are anticipated to fuel the market growth.
Thus, owing to the abovementioned factors, such as government funding, the high prevalence of cardiac and malignant diseases, and market player initiatives such as investments, the market is expected to project significant growth over the forecast period. However, the high cost of the procedure and stringent regulatory scenario are expected to restrain the market's growth over the forecast period.
Human Embryonic Stem Cells Market Trends
Stem Cell Biology Research Segment is Expected to Exhibit Significant Growth in the Forecast Year
Stem cells are biological cells that can differentiate into other types of cells. Additionally, various types of stem cells are used for therapeutic purposes. With multiple applications at the clinical stage for various diseases such as cancer and neurological conditions, many biopharmaceutical companies have explored these extensively in recent times. Stem cell biology research will show better growth owing to the high prevalence of diseases such as Parkinson's disease, cancer, and Others.
The increasing research studies to develop stem cell-based therapies are anticipated to contribute to the segment growth. For instance, in September 2024, the California Institute for Regenerative Medicine (CIRM) granted Cal Poly Humboldt USD 4.4 million to help establish a network of stem cell research Shared Resources Labs (SRLs) across California. Additionally, in March 2024, the University of California, Irvine (UCI) Health presented new clinical trial findings for bemdaneprocel, a promising stem cell-derived treatment for Parkinsonās disease that consistently demonstrated positive outcomes 18 months post-treatment. Thus, the rising funding to boost stem cell biology research is likely to drive the segment growth.
Furthermore, in February 2023, the first patient in the STEM-PD clinical trial (human clinical trial testing a new investigational therapy for Parkinsonās disease) received a transplant at Skane University Hospital in Lund, Sweden. The STEM-PD researchers introduced the completion of dosing for the initial four patients, each receiving the lower dose of cells at 3.5 million cells per putamen, totaling 7 million cells. Therefore, increasing research in the field of stem cells is boosting its adoption, which is contributing to the segment growth.
Additionally, to accelerate stem cell research, the market players invest significantly to boost stem cell research. For instance, in May 2023, StemCures, a United States-based company, revealed a substantial investment of USD 54 million to set up the largest stem cell manufacturing laboratory in Hyderabad, India. Hence, market player initiatives such as investments and geographical expansion to boost stem cell biology research, is expected to boost the segment growth.
Thus, owing to these factors such as increasig clinical trials, government funding and market player initiatives, the segment studied is expected to witness a high growth rate over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America to Hold a Major Share in the Human Embryonic Stem Cells Market Over The Forecast Period
North American region is expected to hold a significant share of the market studied owing to extensive research activities and the region's high burden of chronic diseases and genetic disorders. The United States also shows a high incidence of diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have a high potential for use in treatment and may become a standard of care for these diseases.
The increasing research studies to develop stem cell therapy are anticipated to fuel the country's market growth. For instance, in August 2024, a novel stem cell treatment for heart failure was under investigation in patients at the University of Louisville and UofL Health. This trial marked the first in the United States to evaluate umbilical cord-derived stem cells in heart failure patients and is also the inaugural study to administer cell therapy via intravenous (IV) delivery for this condition.
Additionally, market player initiatives are anticipated to boost the market's growth in the region. For instance, in July 2024, the Minister of Innovation, Science and Industry inaugurated STEMCELL Technologiesā cutting-edge facility located in British Columbia. This project received a substantial boost from a USD 16.9 million (CAD 22.5 million) investment from the Government of Canada. The funding played a crucial role in establishing a brand-new good manufacturing practices (GMP) biomanufacturing facility, enabling STEMCELL Technologies to produce products that meet the stringent regulatory compliance standards necessary for clinical trials in cell therapy, tissue engineering, immunotherapy, gene therapy, and regenerative medicine, ultimately aiming to find cures for cancer and other severe diseases. These developments are expected to drive innovation and growth in the studied market, further solidifying its role in addressing critical healthcare challenges.
Additionally, in May 2024, REPROCELL USA opened its good manufacturing facility (GMP) dedicated to stem cell production. This development allowed the company to produce off-the-shelf GMP-grade human induced pluripotent cells (hiPSC) and human mesenchymal stem cells (hMSC) for both its own use and to meet the demands of therapeutic, pharmaceutical, and biotechnology companies at competitive prices. Such increasing initiatives taken by the market players are expected to drive the growth of the market.
Hence, these factors such as increasing clinical research activities and market player initiatives are expected to influence the growth of the human embryonic stem cells market over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Human Embryonic Stem Cells Industry Overview
The human embryonic stem cells market is moderately competitive due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. The global players in the human embryonic stem cells market are Astellas Pharma Inc., PeproTech Inc., Lineage Cell Therapeutics Inc., Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific, Vertex Pharmaceuticals.
Human Embryonic Stem Cells Market Leaders
-
Merck KGaA
-
STEMCELL Technologies Inc.
-
Thermo Fisher Scientific
-
Lineage cell therapeutics
-
Vertex Pharmaceuticals
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Human Embryonic Stem Cells Market News
- September 2024: The Allen Institute for Cell Science and the New York Stem Cell Foundation (NYSCF) unveiled an innovative collaboration aimed at tackling this crucial challenge by merging two advanced technologies to develop more inclusive cellular models for disease research. This partnership will integrate the structure tags from the Allen Institute for cell science into the NYSCFās diverse collection of ethnically representative stem cell lines.
- September 2024: The Center of PhenoGenomics and the School of Life Sciences at Swiss Federal Institute of Technology Lausanne (EPFL) opened the SCOL (Stem Cell and Organoid Laboratory). This collaborative facility is available to all EPFL research teams and supports the cultivation of organoids and induced pluripotent stem cells (iPSCs).
Human Embryonic Stem Cells Industry Segmentation
Human embryonic stem cells are pluripotent stem cells that are extracted from the inner cell mass of a blastocyst, which is an early-stage pre-implantation embryo. These stem cells are used for the treatment of various diseases.
The human embryonic stem cells market is segmented by application and geography. By application, the market is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
| By Application | Regenerative Medicine | ||
| Stem Cell Biology Research | |||
| Tissue Engineering | |||
| Toxicology Testing | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Human Embryonic Stem Cells Market Research FAQs
How big is the Human Embryonic Stem Cells Market?
The Human Embryonic Stem Cells Market size is expected to reach USD 1.22 billion in 2025 and grow at a CAGR of 9.58% to reach USD 1.93 billion by 2030.
What is the current Human Embryonic Stem Cells Market size?
In 2025, the Human Embryonic Stem Cells Market size is expected to reach USD 1.22 billion.
Who are the key players in Human Embryonic Stem Cells Market?
Merck KGaA, STEMCELL Technologies Inc., Thermo Fisher Scientific, Lineage cell therapeutics and Vertex Pharmaceuticals are the major companies operating in the Human Embryonic Stem Cells Market.
Which is the fastest growing region in Human Embryonic Stem Cells Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Human Embryonic Stem Cells Market?
In 2025, the North America accounts for the largest market share in Human Embryonic Stem Cells Market.
What years does this Human Embryonic Stem Cells Market cover, and what was the market size in 2024?
In 2024, the Human Embryonic Stem Cells Market size was estimated at USD 1.10 billion. The report covers the Human Embryonic Stem Cells Market historical market size for years: 2022, 2023 and 2024. The report also forecasts the Human Embryonic Stem Cells Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Human Embryonic Stem Cells Industry Report
Statistics for the 2025 Human Embryonic Stem Cells market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Human Embryonic Stem Cells analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
